Attoney Docket No. 3477-95

1635
PATENT

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Aubin et al. Serial No.: 10/089,429

Filing Date: November 29, 2002

For: ESTROGEN RELATED RECEPTOR

ERRα, A REGULATOR OF BONE FORMATION

Confirmation No.: 6914 Group Art Unit: 1635

Examiner: Tracy Ann Vivlemore

Date: January 27, 2005

Mail Stop Sequence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an AMENDMENT in the above-identified patent application.

Applicant claims small entity status. See 37 CFR §1.27.

No additional fee is required.

The fee has been calculated as shown below:

(COL. 1)		(COL. 2) (COL. 3)		SMALL ENTITY		OTHER THAN A SMALL ENTITY	
	Claims Remaining After Amendment	Highest Number Previously Paid For	Present Extra	RATE	ADDIT. FEE	<u>OR</u> RATE	ADDIT. FEE
Total	20	23	= 0	x 25=	\$ 0.00	x 50=	\$ 0.00
Indep	4	6	= 0	x100=	\$ 0.00	x200=	\$ 0.00
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM +180= \$ 0.00 +360=				\$ 0.00			
			Total Add. Fe	e \$ 0.00	OR Total	\$0.00	

If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

<sup>&</sup>quot;Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior Amendment or the number of claims originally filed.

Seria Filing	Aubin et al. al No.: 10/089,429 Date: November 29, 2002 Dey Docket No. 3477-96 2
	Please charge my Deposit Account No. 50-0220 in the amount of \$ for
	A check in the amount \$ to cover is enclosed.
	The Commissioner is hereby authorized to charge the appropriate fees associated with this communication or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,

Karen A. Magri Registration No. 41,965

### **CERTIFICATE OF EXPRESS MAILING**

"Express Mail" mailing label number: EV472511319US

Date of Deposit: January 27, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Sequence,

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Sarah Brunmeier

Customer No. 20792

Myers Bigel Sibley & Sajovec, P.A. P. O. Box 37428

Raleigh, North Carolina 27627

Telephone: (919) 854-1400 Facsimile: (919) 854-1401



Please find below and/or attached an Office communication concerning this application or proceeding.





# UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR /	ATTORNEY DOCKET NO.
CONTROL NO.		PATENT IN REEXAMINATION	

EXAMINER

ART UNIT PAPER

20041221

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner for Patents** 

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. '1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. "1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.R.F. "1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. '1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. '1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tracy Vivlemore whose telephone number is 571-272-2914. The examiner can normally be reached on Mon-Fri 8:45-5:15.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached on 571-272-0760. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

SEAN MCGARITY PRIMARY EXAMINER

T۷

December 21, 2004

Application No.: 10/089429

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's	,
attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 11	14
OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking	٦g
notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).	

$\overline{X}$	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence
	Listing" as required by 37 C.F.R. 1.821(c).

X	37 C.F.R. 1.821(e).	in computer	readable form has r	iot been submitted	as required by
ш	37 C.F.R. 1.821(e).				

$\Box$	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822
	content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822
	and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing".

П	<ol><li>The computer readable form that has been filed with this application has been found to be damaged</li></ol>
ل	and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute
	computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

П	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the
Ш	"Sequence Listing" as required by 37 C.F.R. 1.821(e).

X	7. Other:	Sequences in the specification not identified by SEQ	ID NO:#
١, ,			

#### **Applicant Must Provide:**

An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing". (If the unidentified sequences are not provided on the CRF)

An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. (If the unidentified sequences are not provided in the paper copy)

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). (If a new paper and/or CRF are required)

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY